Meric JB - Search Results

1

Meric JB, Rixe O, Khayat D. Meric JB, et al. Drugs Today (Barc). 2003;39 Suppl C:17-38. Drugs Today (Barc). 2003. PMID: 14988744 Review.

2

Serum interleukin-6 concentrations as predictive factor of time to progression in metastatic malignant melanoma patients treated by biochemotherapy: a retrospective study.

Mouawad R, Rixe O, Meric JB, Khayat D, Soubrane C. Mouawad R, et al. Among authors: meric jb. Cytokines Cell Mol Ther. 2002;7(4):151-6. doi: 10.1080/13684730210002328. Cytokines Cell Mol Ther. 2002. PMID: 14660055

3

Blood glucose levels in patients with metastatic renal cell carcinoma treated with sunitinib.

Billemont B, Medioni J, Taillade L, Helley D, Meric JB, Rixe O, Oudard S. Billemont B, et al. Among authors: meric jb. Br J Cancer. 2008 Nov 4;99(9):1380-2. doi: 10.1038/sj.bjc.6604709. Epub 2008 Oct 7. Br J Cancer. 2008. PMID: 18841151 Free PMC article.

4

Pretreatment serum interleukin-6 concentration as a prognostic factor of overall survival in metastatic malignant melanoma patients treated with biochemotherapy: a retrospective study.

Soubrane C, Rixe O, Meric JB, Khayat D, Mouawad R. Soubrane C, et al. Among authors: meric jb. Melanoma Res. 2005 Jun;15(3):199-204. doi: 10.1097/00008390-200506000-00009. Melanoma Res. 2005. PMID: 15917702

5

Comparison of the efficacy and safety of combinations of metopimazine or ondansetron with methylprednisolone in the prevention of delayed emesis in patients receiving chemotherapy.

Bloch J, Rixe O, Meric JB, Delgado A, Khayat D. Bloch J, et al. Among authors: meric jb. Curr Med Res Opin. 2005 Nov;21(11):1763-71. doi: 10.1185/030079905X61802. Curr Med Res Opin. 2005. PMID: 16307696 Clinical Trial.

6

Biochemotherapy for advanced melanoma: maybe it is real.

Khayat D, Bernard-Marty C, Meric JB, Rixe O. Khayat D, et al. Among authors: meric jb. J Clin Oncol. 2002 May 15;20(10):2411-4. doi: 10.1200/JCO.2002.20.10.2411. J Clin Oncol. 2002. PMID: 12011117 No abstract available.

7

Cyclooxygenase-2 as a target for anticancer drug development.

Méric JB, Rottey S, Olaussen K, Soria JC, Khayat D, Rixe O, Spano JP. Méric JB, et al. Crit Rev Oncol Hematol. 2006 Jul;59(1):51-64. doi: 10.1016/j.critrevonc.2006.01.003. Epub 2006 Mar 13. Crit Rev Oncol Hematol. 2006. PMID: 16531064 Review.

8

[Anemia in cancer patients before treatment].

Auclerc G, Meric JB, Pommeyrol A, Rixe O, Khayat D. Auclerc G, et al. Among authors: meric jb. Bull Cancer. 2003 Apr;90 Spec No:S128-32. Bull Cancer. 2003. PMID: 12856424 Review. French.

9

Multicenter, phase II study of axitinib, a selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, in patients with metastatic melanoma.

Fruehauf J, Lutzky J, McDermott D, Brown CK, Meric JB, Rosbrook B, Shalinsky DR, Liau KF, Niethammer AG, Kim S, Rixe O. Fruehauf J, et al. Among authors: meric jb. Clin Cancer Res. 2011 Dec 1;17(23):7462-9. doi: 10.1158/1078-0432.CCR-11-0534. Epub 2011 Oct 5. Clin Cancer Res. 2011. PMID: 21976544 Clinical Trial.

10

[Angiogenesis and renal cell carcinoma].

Billemont B, Méric JB, Izzedine H, Taillade L, Sultan-Amar V, Rixe O. Billemont B, et al. Among authors: meric jb. Bull Cancer. 2007 Jul;94 Spec No:S232-40. Bull Cancer. 2007. PMID: 17846009 Review. French.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

36 results

Search Page

Filters